On the contrary, the combination of BRAF and MEK inhibitors has generated unprecedented response rates in patients diagnosed with these aggressive thyroid carcinomas, and validation of the published preliminary results is eagerly awaited with the hope that it may provide durable benefits comparable to those reported in BRAF-mutant melanoma. Here, MAP2K7 is linked to thyroid gland carcinoma.